# A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

> **NCT06672939** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 125 (estimated)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06672939
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2027-02
- **Final completion:** 2027-03
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672939, "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT06672939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*